CLAIMS

1. A composition comprising a secretome obtained by culturing a myeloid progenitor cell in the presence of an agent that activates the myeloid progenitor cell to an activated immune cell, wherein the secretome comprises two or more factors selected from the group consisting of CCL2/MCP-1, MIP-1α/MIP-1β, CCL5/RANTES, MIF, IL-1ra/IL-IF3, IL-8 and Serpin E1 / PAI-1.

2. The composition according to claim 1, wherein the secretome comprises a protein comprising a cytokine, a hormone, an antibody, a growth factor, an extracellular matrix protein, a shed receptor, a coagulation factor, an adhesion molecule, a protease, a kinase and/or a glycoprotein.

3. The composition according to any one of the preceding claims, wherein the immune cell is a macrophage expressing CD11b and/or CD163.

4. The composition according to any one of the preceding claims, wherein the secretome is a macrophage-derived secretome.

5. The composition according to any one of the preceding claims, wherein the agent comprises a stimulating agent or a suppressing agent.

6. The composition according to any one of the preceding claims, wherein the agent is a myeloid stimulating agent.

7. The composition according to any one of the preceding claims, wherein the agent is PMA and/or IL-4.

8. The composition according to any one of the preceding claims, wherein the secretome sustains cell growth, cell proliferation, cryopreserve cells, elongates telomere length in cancer cells, involved in metabolic reprogramming, identifying drug resistance and / or preventing cancer cell death under nutrient stress conditions.

9. A composition according to any one of the preceding claims for use in tissue regeneration.

10. A method of generating a macrophage-derived secretome comprising

culturing a myeloid progenitor cell in the presence of a stimulating agent to thereby generate an activated immune cell population and harvesting the secretome from the generated activated immune cell population,

wherein the secretome comprises two or more factors selected from the group consisting of CCL2/MCP-1, MIP-1α/MIP-1β, CCL5/RANTES, MIF, IL-1ra/IL-IF3, IL-8 and Serpin E1 / PAI-1.

11. The method according to claim 10 further comprising culturing the activated immune cell in the presence of a diseased cell.

12. The method according to claims 10 or 11, wherein the diseased cell is a cell from a proliferative disease.

13. The method according to claims 10 to 12, wherein the diseased cell is a tumour cell from a brain tumour, an atypical teratoid rhabdoid tumour (ATRT) and/or medulloblastoma.

14. A method of screening a drug comprising culturing the drug with a diseased cell in the presence of the composition of claims 1 to 8.

15. A method of culturing a proliferative cell comprising culturing the proliferative cell in a composition according to claims 1 to 8.